(Q32045021)

English

Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

5 July 2017

Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug (English)

1 reference

Europe PubMed Central

5 July 2017

0 references

ankylosing spondylitis

1 reference

based on heuristic

inferred from title

author name string

Dougados M

1

1 reference

Europe PubMed Central

5 July 2017

Béhier JM

2

1 reference

Europe PubMed Central

5 July 2017

Jolchine I

3

1 reference

Europe PubMed Central

5 July 2017

Calin A

4

1 reference

Europe PubMed Central

5 July 2017

van der Heijde D

5

1 reference

Europe PubMed Central

5 July 2017

Olivieri I

6

1 reference

Europe PubMed Central

5 July 2017

Zeidler H

7

1 reference

Europe PubMed Central

5 July 2017

Herman H

8

1 reference

Europe PubMed Central

5 July 2017

publication date

1 January 2001

1 reference

Europe PubMed Central

5 July 2017

Arthritis & Rheumatology

1 reference

Europe PubMed Central

5 July 2017

44

1 reference

Europe PubMed Central

5 July 2017

1

1 reference

Europe PubMed Central

5 July 2017

180-185

1 reference

Europe PubMed Central

5 July 2017

Endogenous glucocorticoids regulate an inducible cyclooxygenase enzyme

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200101%2944%3A1%3C180%3A%3AAID-ANR24%3E3.0.CO%3B2-K

21 January 2018

Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200101%2944%3A1%3C180%3A%3AAID-ANR24%3E3.0.CO%3B2-K

21 January 2018

Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200101%2944%3A1%3C180%3A%3AAID-ANR24%3E3.0.CO%3B2-K

21 January 2018

Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison.

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200101%2944%3A1%3C180%3A%3AAID-ANR24%3E3.0.CO%3B2-K

21 January 2018

Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200101%2944%3A1%3C180%3A%3AAID-ANR24%3E3.0.CO%3B2-K

21 January 2018

Ketoprofen: a preliminary report of its pharmacological activity and therapeutic efficacy in rheumatic disorders.

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200101%2944%3A1%3C180%3A%3AAID-ANR24%3E3.0.CO%3B2-K

21 January 2018

Ketoprofen: a review of its pharmacologic and clinical properties

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200101%2944%3A1%3C180%3A%3AAID-ANR24%3E3.0.CO%3B2-K

21 January 2018

The relationship of clinical and laboratory measurements to radiological change in ankylosing spondylitis.

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200101%2944%3A1%3C180%3A%3AAID-ANR24%3E3.0.CO%3B2-K

21 January 2018

Identifiers

10.1002/1529-0131(200101)44:1<180::AID-ANR24>3.0.CO;2-K

1 reference

Europe PubMed Central

5 July 2017

1 reference

Europe PubMed Central

5 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q32045021&oldid=1994705672"